Login to Your Account

Momenta's Momentous Event

Sanofi Circling Wagons After FDA Clears Generic Lovenox

By Randy Osborne

Monday, August 2, 2010
Momenta Pharmaceuticals Inc.'s surprising good fortune with the FDA's nod last week for the company's generic Lovenox sent shares skyrocketing 82 percent and capped five years of exchanges between the regulatory agency and Momenta with partner Sandoz, the generic unit of Basel, Switzerland-based Novartis AG. It also may have sent an ominous signal to Teva Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription